Checks how long protection from a quadrivalent HPV vaccine lasts in Chinese women
Follows immune levels in healthy Chinese women aged 9 to 45 after HPV vaccination.
Plain-language title generated from the registry record
Registry title: Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Key facts
- Where
- Mianyang and Yangchun, ChinaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women and girls aged 9 to 45 who already took part in an earlier HPV vaccine trial and received all three vaccine doses. It checks how long their immune protection lasts.
- Age
- 9 to 45 years
- Sex
- Female only
- Earlier treatment
- Must have taken part in trial 4-HPV-3001 or 4-HPV-3002, finished all three HPV quadrivalent vaccine doses (months 0, 2 and 6), and given a blood sample at month 7.
Main reasons for not taking part
- Taking part or planning to take part in another drug or vaccine trial
- A bleeding or clotting problem, such as low platelets, that makes blood draws unsafe
- Any condition the investigator thinks could disturb the immune persistence check
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 9 and 45 years old?
Source: NCT05371353, who can take part
Where in China
- Center for Disease Control and PreventionMianyang, ChinaTaking people
- Yangchun Center For Disease Prevention And ControlYangchun, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanghai Bovax Biotechnology Co., Ltd.
- Trial code
- NCT05371353
- Record updated
- 17 April 2024
- Original description
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.Read full original descriptionShow less
Evaluating the Immune Persistence of Recombination Quadrivalent HPV Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomized Clinical Trial
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
Inclusion: Subjects who participated in the phase III clinical trial of non inferior efficacy of HPV tetravalent vaccine of Yangchun Center for Disease Control and Prevention (protocol No.: 4-HPV-3001), completed three doses of HPV quadrivalent vaccine and provided blood sample at months 7; Or subjects who have participated in the bridging study of HPV quadrivalent vaccine of Mianyang Center for Disease Control and Prevention (scheme No.: 4-HPV-3002), completed the whole vaccine schedule at month 0，2，6, and provided blood sample at months 7; The subjects aged 9 to 17 years old at Mianyang site and their legal guardian should provide legal indentification; the subjects aged over 18 years old should provide legal indentification; The subject voluntarily agrees to enroll in this study. If the subject is a minor, both the subject and subject's legal guardian should voluntarily agree to enroll in this study and sign an informed consent form; Be able to understand the study procedures and promise to participate in regular follow-ups under the requirements.
Exclusion: Enrolling or plan to enroll in other clinical trials (drugs or vaccines) (except that the observational clinical study and the subjects at Mianyang site are still in the post exemption safety follow-up stage of the 4-HPV-3002 trial); According to the investigator's judgment, the subject has any condition may interfere with process of evaluation of immune persistence; Suffering from thrombocytopenia or any coagulation dysfunction that can be a contraindication to blood collection (such as coagulation factor deficiency, coagulation diseases, platelet abnormalities, etc.).